CA
NZ
UK
AU
IND
US
● Second quarter revenue rose 48% to about $23 billion on 60% volume growth.
● The trial targets 237 participants, randomized two to one, with a 12-month primary endpoint.
● Pacira sold iovera to Zimmer Biomet, with up to $70 million in milestones possible.
● Consensus is about 73 cents adjusted EPS on revenue near $15.9 billion, per outside estimates.
● Beverage revenue rose about 82% to roughly $101.5 million on the BrewDog acquisition.
● Medical care ratio improved to 88.4% from 89.9%, aided by roughly $610 million reserve benefit.
● Second-quarter net revenue was about $77.5 million, up about 22%, led by MACI.
Achieve Life Sciences (NASDAQ:ACHV) shares are indicated down 3.03% at $6.72 in premarket, after rising 5.96% to close at $6.93 on Tuesday. No company-specific catalyst was identified for the dip, and the healthcare sector ETF is also softer, down about 0.8%, as investors weigh …
Axogen (NASDAQ:AXGN) shares are indicated up 19.83% at $44.89 in premarket after third-quarter results topped expectations and management raised its 2026 outlook. Revenue of $75.8 million, up 26.2% from $60.1 million, beat the roughly $73.2 million consensus, and adjusted EPS of $0.21 beat the …
Boston Scientific (NYSE:BSX) shares are indicated down 6.08% at $42.32 in premarket after third-quarter results that were roughly in line but a cut to the 2026 outlook as the August cyberattack weighs on the business. Revenue of $5.14 billion was up 1.5%, and adjusted …
Please wait processing your request...